Table 2 Use of aromatase inhibitors (final analysis set)
| Â | Â | Final analysis set |
|---|---|---|
|  | Treatment duration (months) | (N = 486) n (%) |
Anastrozole | <6 | 1 (0.2) |
|  | 6–12 | 5 (1.2) |
|  | 12–18 | 1 (0.2) |
|  | 18–24 | 3 (0.7) |
| Â | >24 | 416 (97.7) |
| Â | Total | 426 (100) |
| Â | Missing | 15 |
Anastrozole/exemestane | >24 | 1 (100) |
| Â | Total | 1 (100) |
Anastrozole/letrozole | >24 | 5 (100) |
| Â | Total | 5 (100) |
Exemestane | >24 | 10 (100) |
| Â | Total | 10 (100) |
Letrozole | 6–12 | 2 (6.9) |
| Â | >24 | 27 (93.1) |
| Â | Total | 29 (100) |